Loading clinical trials...
Loading clinical trials...
Phase 2b Study of BPZE1 Intranasal Pertussis Vaccine in Adults to Assess Immunological Response and Safety Profile of 1-Dose (Prime) and 2-Doses (Prime+Boost) Schedule, Compared to a Boostrix™ Prime Dose With or Without a BPZE1 Boost Dose
Conditions
Interventions
BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Locations
3
United States
Rapid medical Research Inc
Cleveland, Ohio, United States
DM Clinical Research
Tomball, Texas, United States
Advanced Clinical Research
West Jordan, Utah, United States
Start Date
June 15, 2019
Primary Completion Date
February 14, 2020
Completion Date
June 24, 2020
Last Updated
June 27, 2023
NCT07203755
NCT07112144
NCT06947499
NCT06803524
NCT06258057
NCT06708286
Lead Sponsor
ILiAD Biotechnologies
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions